Effect of atenolol versus ivabradine on heart rate variability in patients of schizophrenia with clozapine-induced tachycardia: a randomized controlled trial.
Amit Bahmania, Manisha Kar, Tathagata Biswas et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial compared the effects of atenolol and ivabradine on heart rate variability (HRV) in patients with treatment-resistant schizophrenia experiencing clozapine-induced tachycardia. Conducted over 20 months, the study found that both medications significantly reduced pulse rates, but atenolol showed significant improvements in high-frequency power and LF/HF ratio, while ivabradine did not demonstrate significant changes in HRV parameters.
Key findings
- Atenolol reduced pulse rates by -20.56 ± 13.00, p<0.001.
- Ivabradine reduced pulse rates by -21.855 ± 12.873, p<0.001.
- Atenolol group showed significant improvements in high-frequency power (p=0.048) and LF/HF ratio (p=0.044).
- No significant changes in HRV parameters were observed in the ivabradine group.
Why it matters
Understanding the effects of these medications on heart rate variability is crucial for managing clozapine-induced tachycardia in patients with treatment-resistant schizophrenia, as it can influence treatment decisions and patient outcomes.